Zhihui Amy Liu
YOU?
Author Swipe
View article: Understanding Equity, Diversity, and Inclusion Within Canadian Radiation Oncology Training Programs: A National Survey of Residents and Fellows
Understanding Equity, Diversity, and Inclusion Within Canadian Radiation Oncology Training Programs: A National Survey of Residents and Fellows Open
Background: This study characterizes the current representation of sociodemographic groups within Canadian radiation oncology training programs and trainees’ lived experiences. Methods: A 59-item ethics-approved, bilingual survey assessed …
View article: MRI-guided brachytherapy for vaginal recurrence of endometrial cancer
MRI-guided brachytherapy for vaginal recurrence of endometrial cancer Open
View article: Understanding Equity, Diversity, and Inclusion Within Canadian Radiation Oncology Training Programs: Experiences of Residents and Fellows
Understanding Equity, Diversity, and Inclusion Within Canadian Radiation Oncology Training Programs: Experiences of Residents and Fellows Open
Background: This study characterizes the current representation of sociodemographic groups within Canadian radiation oncology training programs and trainees’ lived experiences. Methods: A 59-item ethics approved bilingual survey assessed: …
View article: Preoperative intensity‐modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue
Preoperative intensity‐modulated radiation therapy in lower extremity soft tissue sarcomas with and without dose avoidance of uninvolved skin/subcutaneous tissue Open
Background The objective of this study was to evaluate whether dosimetric sparing of uninvolved normal tissues, including skin/subcutaneous flaps , affects acute and late toxicities in preoperative image‐guided intensity‐modulated radiatio…
View article: T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab
T cell receptor repertoire in cell-free DNA as a proxy for tumor infiltrates in patients treated with pembrolizumab Open
Profiling tumor and systemic T cell receptor (TCR) repertoires can identify features associated with the clinical benefit of patients with cancer on immune checkpoint blockade therapy. This study reports on the diversity and specificity an…
View article: Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer Open
View article: Collecting Data on the Social Determinants of Health to Advance Health Equity in Cancer Care in Canada: Patient and Community Perspectives
Collecting Data on the Social Determinants of Health to Advance Health Equity in Cancer Care in Canada: Patient and Community Perspectives Open
Despite advances in cancer care, disparities persist. The collection of the social determinants of health (SDOH) is fundamental to addressing disparities. However, SDOH are inconsistently collected in many regions of the world. This two-ph…
View article: Author Correction: Patient perceptions of empathy in physician and artificial intelligence chatbot responses to patient questions about cancer
Author Correction: Patient perceptions of empathy in physician and artificial intelligence chatbot responses to patient questions about cancer Open
View article: Patient perceptions of empathy in physician and artificial intelligence chatbot responses to patient questions about cancer
Patient perceptions of empathy in physician and artificial intelligence chatbot responses to patient questions about cancer Open
View article: Clinical impact of radiotherapy quality assurance results in contemporary cancer trials: a systematic review and meta-analysis
Clinical impact of radiotherapy quality assurance results in contemporary cancer trials: a systematic review and meta-analysis Open
Quality of radiotherapy continues to have an important, measurable impact on patient outcomes in oncology RCTs, and rigorous, real-time RTQA procedures may diminish these effects by standardizing RT. Future trials should provide patient ou…
View article: Impact of Excluding Internal Mammary Node Coverage on Musculoskeletal Dosimetry in Breast Radiotherapy
Impact of Excluding Internal Mammary Node Coverage on Musculoskeletal Dosimetry in Breast Radiotherapy Open
View article: Combination of FDG PET/CT radiomics and clinical parameters for outcome prediction in patients with non-Hodgkin’s lymphoma
Combination of FDG PET/CT radiomics and clinical parameters for outcome prediction in patients with non-Hodgkin’s lymphoma Open
Purpose The purposes was to build model incorporating PET + computed tomography (CT) radiomics features from baseline PET/CT + clinical parameters to predict outcomes in patients with non-Hodgkin lymphomas. Methods Cohort of 138 patients w…
View article: Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab Open
PURPOSE Immune gene expression signatures are emerging as potential biomarkers for immunotherapy (IO). VIGex is a 12-gene expression classifier developed in both nCounter (Nanostring) and RNA sequencing (RNA-seq) assays and analytically va…
View article: Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer
Clinical Outcomes of 3 Versus 4 Fractions of Magnetic Resonance Image-Guided Brachytherapy in Cervical Cancer Open
View article: OTHR-30. THE CLINICAL AND BIOLOGICAL LANDSCAPE OF CNS CANCERS IN CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY: AN IRRDC COHORT STUDY
OTHR-30. THE CLINICAL AND BIOLOGICAL LANDSCAPE OF CNS CANCERS IN CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY: AN IRRDC COHORT STUDY Open
BACKGROUND Constitutional mismatch repair deficiency (CMMRD) is an aggressive cancer predisposition syndrome. As a lack of data contributes to management challenges and inferior outcomes, especially in central nervous system (CNS) cancers,…
View article: Supplementary Figure 14 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 14 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Cancer-specific methylation (CSM) and fragment length scores (FLS) are moderately correlated. CSM and FLS scores were computed for each sample. Correlation testing between FLS and log-adjusted CSM was performed using Spearman's method.
View article: Supplementary Figure 13 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 13 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Increase in both ctDNA metrics identifies a subgroup with particularly poor outcome. Post-hoc analysis of ΔCSM and ΔCMC together demonstrates that a decrease in either metric was sufficient to result in significantly improved PFS and OS, w…
View article: Data from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Data from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles us…
View article: Supplementary Figure 11 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 11 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Multivariable analysis of OS and PFS using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a bespoke targeted approach across the trial cohort. At both baseline and cycle 3, patients w…
View article: Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Predicting survival outcomes using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a tumor-informed bespoke approach across the trial cohort. At both baseline and cycle 3, patients wer…
View article: Data from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Data from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing of matched tumor tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles us…
View article: Supplementary Figure 9 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 9 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Multivariable analysis of survival using cancer-specific methylation (CSM) scores at baseline and cycle 3 of pembrolizumab. We computed CSM scores across the trial cohort. At both baseline and cycle 3, patients were split into above- or be…
View article: Supplementary Figure 3 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 3 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Examples of cancer-specific methylation score calculation. Cancer-specific methylation scores were computed using the sum of inferred absolute methylation values for all reads overlapping an independently-trained cancer-specific signature.…
View article: Supplementary Figure 16 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 16 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Multivariate Cox analysis of the change in fragment length score (FLS) from baseline to cycle 3 of pembrolizumab. Covariates in clude cohort, PD-L1 expression, and tumor mutation burden.
View article: Supplementary Figure 15 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 15 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Predicting survival outcomes using fragment length score (FLS) at baseline and cycle 3 of pembrolizumab. FLS was determined as the mean of the log2 transformed cancer-to-normal ratio of the length of each fragment in a given cfMeDIP-seq sa…
View article: Supplementary Figure 2 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 2 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Overall survival (OS) and progression free survival (PFS) in included patients by cohort. (A) Kaplan-meier curves are shown indicating the OS and PFS of patients in five histology-specific cohorts. (B) Forest plot of the hazard ratios for …
View article: Supplementary Figure 8 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 8 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Predicting survival outcomes using cancer-specific methylation (CSM) scores at baseline and cycle 3 of pembrolizumab. We computed CSM scores across the trial cohort. At both baseline and cycle 3, patients were split into above- and below-m…
View article: Supplementary Figure 6 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 6 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Non-negative matrix factorization identifies characteristic cancer-associated signatures of shorter fragment lengths and greater nucleosome core occupancy. (A) Genome-wide fragment lengths were used as features in a two-component non-negat…
View article: Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 12 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Multivariate Cox analysis of change in cancer mutation concentration (CMC) from baseline to cycle 3 of pembrolizumab. Covariates include cohort, PD-L1 expression, and tumor mutation burden
View article: Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
Supplementary Figure 10 from Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors Open
Predicting survival outcomes using cancer mutation concentration (CMC) at baseline and cycle 3 of pembrolizumab. CMC was determined using a tumor-informed bespoke approach across the trial cohort. At both baseline and cycle 3, patients wer…